Momsone 0.1% Cream — Mometasone Furoate — SEDICO — Topical Corticosteroid
1. Disclaimer
This information is intended for general educational and reference purposes and does not replace the approved product leaflet, medical diagnosis, individualized treatment, or the advice of a physician or pharmacist. The locally approved prescribing information should be followed, particularly for children, pregnancy, breastfeeding, extensive skin disease, infection, or prolonged corticosteroid treatment.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
Approved indications, contraindications, treatment duration, age restrictions, storage requirements, pack sizes, and other regulatory information can differ between countries and products containing the same active ingredient. For use in Egypt, the latest Egyptian Drug Authority (EDA)-approved Momsone carton and package leaflet should take precedence where product-specific instructions differ from international references.
2. Summary
Momsone 0.1% Cream is a topical corticosteroid containing mometasone furoate 1 mg/g (0.1% w/w). It is used to relieve inflammatory and pruritic manifestations of corticosteroid-responsive skin disorders.
Mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties.
Its potency classification varies according to the classification system used. Current U.S. prescribing information describes mometasone furoate 0.1% cream as being in the medium range of potency, whereas current UK prescribing information classifies it as a potent (Group III) corticosteroid.
Systemic absorption through intact skin is low, but exposure may increase when treatment involves inflamed or damaged skin, large surface areas, prolonged use, skin folds, or occlusion. Children are more susceptible to systemic corticosteroid effects because of their greater skin-surface-area-to-body-mass ratio.
3. Brand Name
Momsone 0.1% Cream
The Egyptian product presentation described here is Momsone 0.1% Cream, 20 g, manufactured by SEDICO.
4. Category
- Topical corticosteroid / topical glucocorticoid.
- Dermatological anti-inflammatory agent.
- ATC code: D07AC13.
- Potency: described as medium range in U.S. labeling and potent/Group III in current UK labeling.
5. Active Ingredient
Each gram of cream contains:
Mometasone furoate 1 mg (0.1% w/w).
The Momsone product information describes the ingredient as mometasone furoate anhydrous.
Mometasone furoate is a synthetic corticosteroid. Its molecular formula is C₂₇H₃₀Cl₂O₆. It should not be described as a fluorinated corticosteroid because its molecular structure contains chlorine atoms but no fluorine.
6. Pharmaceutical Form & Strength
Pharmaceutical form: Cream for cutaneous use.
Strength: Mometasone furoate 0.1% w/w = 1 mg/g.
Egyptian product information identifies a 20-g tube presentation.
7. Manufacturer & Marketing Authorization Holder
Manufacturer / product company:
SEDICO Pharmaceutical Co., Egypt.
The precise current legal Marketing Authorization Holder and Egyptian registration details should be verified from the latest EDA-approved Momsone carton or package leaflet, as publicly accessible medicine databases may not reliably reproduce current regulatory-registration details.
8. Mechanism of Action
Like other topical corticosteroids, mometasone furoate produces anti-inflammatory, antipruritic, and vasoconstrictive effects.
The exact mechanism responsible for the anti-inflammatory action of topical corticosteroids is not completely established. Corticosteroids are thought to induce phospholipase A₂-inhibitory proteins, collectively known as lipocortins. These proteins reduce release of arachidonic acid and consequently decrease formation of inflammatory mediators such as prostaglandins and leukotrienes.
Glucocorticoid-receptor-mediated regulation of gene transcription also contributes to the broader anti-inflammatory actions of corticosteroids.
9. Spectrum of Activity
An antimicrobial spectrum is not applicable to mometasone furoate.
Mometasone is a corticosteroid and has no direct antibacterial, antifungal, antiviral, or antiparasitic action.
If a bacterial or fungal infection is present or develops during treatment, appropriate antimicrobial therapy may be required. If an infection does not respond promptly, current prescribing information recommends discontinuing the corticosteroid until the infection has been adequately controlled.
10. Pharmacokinetics
Percutaneous absorption of topical corticosteroids depends on factors including the formulation, integrity of the epidermal barrier, inflammation, treated surface area, duration of treatment, and occlusion.
Human studies indicate that approximately 0.4% of an applied dose of mometasone furoate 0.1% cream enters the systemic circulation after 8 hours of contact with normal skin without occlusion. Inflammation or other skin disease can increase percutaneous absorption.
Current UK pharmacokinetic information additionally reports that systemic absorption is minimal and that the majority of the absorbed quantity is excreted within approximately 72 hours after application.
The figure 0.4%, rather than a combined “0.4–0.7%,” is therefore the appropriate value specifically supported for mometasone furoate 0.1% cream under the conditions described above.
11. Indications
Momsone 0.1% Cream is intended for the:
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Current international mometasone furoate cream labeling includes conditions such as:
- Atopic dermatitis.
- Psoriasis responsive to topical corticosteroids.
The current UK SmPC specifies psoriasis excluding widespread plaque psoriasis, whereas current U.S. labeling uses the broader indication of corticosteroid-responsive dermatoses in patients aged 2 years and older.
The locally approved Momsone indication should determine use in Egypt.
12. Administration
For cutaneous use only.
Apply a thin film to the affected skin once daily and gently rub it in, unless otherwise directed by the prescribing physician.
Treatment should be discontinued when adequate control has been achieved.
If no improvement is seen within approximately 2 weeks, current U.S. labeling recommends reassessment of the diagnosis rather than continuing treatment without review.
Do not use occlusive dressings unless specifically directed by a physician. Diapers and plastic pants can function as occlusive dressings and increase corticosteroid absorption.
Avoid routine use on the face, groin, or axillae unless directed by a physician. U.S. labeling specifically advises avoiding these areas. Current UK mometasone cream labeling permits treatment of the face when clinically necessary but limits treatment to the least amount required and to no more than 5 days.
Avoid contact with the eyes. The cream is not intended for oral, ophthalmic, or intravaginal use. Current UK labeling specifically states that it should not be used ophthalmically, including on the eyelids.
13. Method of Preparation
No preparation, dilution, or reconstitution is required.
Momsone is supplied as a ready-to-use topical cream.
Apply only the prescribed amount directly to the affected skin.
14. Contraindications
According to the Momsone product information, treatment should not be used in patients with a history of hypersensitivity to corticosteroids or any ingredient of the product.
Regulatory contraindications differ between jurisdictions.
The current UK SmPC for mometasone furoate 0.1% cream additionally lists hypersensitivity to mometasone furoate, other corticosteroids, or excipients and contraindicates use in conditions including:
- Facial rosacea.
- Acne vulgaris.
- Skin atrophy.
- Perioral dermatitis.
- Perianal or genital pruritus.
- Napkin/diaper eruptions.
- Untreated bacterial, fungal, viral, or parasitic skin infections.
- Herpes simplex, herpes zoster, chickenpox, molluscum contagiosum and certain other viral lesions.
- Cutaneous tuberculosis.
- Syphilitic skin lesions.
- Post-vaccination skin reactions.
- Wounds or ulcerated skin.
In contrast, the current U.S. generic mometasone furoate cream label lists no formal contraindications, while addressing infections and other risks under warnings and precautions.
Therefore, the contraindications on the locally approved Momsone leaflet should be followed for the Egyptian product.
15. Warnings & Precautions
Systemic absorption of topical corticosteroids can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, potentially resulting in glucocorticoid insufficiency after withdrawal.
Cushing's syndrome, hyperglycemia, and glucosuria may also occur if sufficient systemic absorption develops.
Risk increases with factors such as:
- Treatment of large skin areas.
- Prolonged treatment.
- Damaged or inflamed skin.
- Occlusive dressings.
- Treatment of flexural areas.
- Pediatric age.
If irritation or sensitization develops, treatment should be stopped and appropriate management instituted.
If a skin infection develops, suitable antibacterial or antifungal treatment should be used. If the response is not prompt, mometasone should be discontinued until the infection is adequately controlled.
Long-term continuous use should be avoided.
Topical corticosteroids may cause problems when used in psoriasis, including rebound relapse, development of tolerance, pustular psoriasis, and local or systemic toxicity, particularly where skin-barrier function is impaired. Careful supervision is therefore recommended.
Visual disturbances:
Topical corticosteroids have been associated with blurred vision and other ocular complications. Cataract, glaucoma, and the rare disorder central serous chorioretinopathy have been reported in association with systemic or topical corticosteroid exposure. Persistent or significant visual symptoms should be medically evaluated.
Topical steroid withdrawal/rebound:
Long-term continuous or inappropriate use of topical corticosteroids can be followed by rebound inflammation or topical steroid withdrawal reactions, including marked redness, burning, stinging, itching, peeling, and sometimes pustulation extending beyond the original treatment area. Current UK labeling advises avoiding abrupt discontinuation after prolonged use of potent topical corticosteroids and recommends cautious reduction where appropriate.
16. Drug Interactions
Specific drug-drug interaction studies have not been conducted with mometasone furoate cream according to current U.S. prescribing information.
Regulatory information is not completely uniform.
The current Elocon UK SmPC states “None stated” under medicinal-product interactions.
However, the Glenmark Mometasone Furoate 0.1% w/w Cream UK SmPC, updated June 2026, states that drugs inhibiting CYP3A, including cobicistat, ritonavir, and itraconazole, can inhibit corticosteroid metabolism and increase systemic exposure. It notes that the clinical importance depends on factors including the corticosteroid dose and potency of the CYP3A inhibitor.
Because systemic absorption of correctly used mometasone cream is ordinarily low, the practical significance of this interaction is likely to depend strongly on the extent of systemic exposure. Particular caution is reasonable with prolonged treatment, large treated areas, damaged skin, or occlusion.
17. Side Effects
Mometasone furoate cream is generally well tolerated when used appropriately.
Reported or recognized local adverse effects include:
- Burning.
- Stinging or paraesthesia.
- Pruritus.
- Irritation.
- Dryness.
- Folliculitis.
- Furunculosis/furuncles.
- Skin atrophy and thinning.
- Shiny skin.
- Loss of skin elasticity or normal markings.
- Telangiectasia.
- Bruising.
- Hypertrichosis.
- Acneiform eruptions.
- Hypopigmentation.
- Perioral dermatitis.
- Allergic contact dermatitis.
- Striae.
- Miliaria.
- Skin maceration.
- Secondary infection.
- Rosacea or rosacea-like dermatitis.
- Application-site pain or reactions.
In controlled U.S. clinical trials, the reported treatment-associated adverse reactions included burning, pruritus, and skin atrophy.
Systemic corticosteroid effects may occur after excessive absorption and include HPA-axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, and adrenal insufficiency.
Children can be particularly susceptible to systemic corticosteroid toxicity and growth-related effects during excessive or chronic exposure.
Blurred vision has also been reported with topical mometasone, and corticosteroid-associated cataract, glaucoma, or central serous chorioretinopathy should be considered when clinically relevant visual symptoms occur.
18. Use in Special Populations
Children
Mometasone furoate 0.1% cream should not be routinely used below 2 years of age, because safety and efficacy have not been established in this age group.
Children are more susceptible than adults to HPA-axis suppression and systemic corticosteroid toxicity because of their greater skin-surface-area-to-body-mass ratio.
In a U.S. safety study involving children aged 6–23 months, HPA-axis suppression occurred in approximately 16% of evaluated subjects after once-daily mometasone furoate 0.1% cream for approximately 3 weeks over a mean treated body surface area of 41%. This age group is below the recommended age for routine use.
Treatment-duration recommendations differ between regulatory jurisdictions:
- Current U.S. labeling states that safety and efficacy in pediatric patients for more than 3 weeks have not been established.
- Current UK Glenmark labeling states that use in children should be limited to the least amount compatible with an effective regimen and that treatment duration should be no more than 5 days.
For Momsone in Egypt, the locally approved product leaflet should determine the permitted pediatric treatment duration.
Pregnancy
Adequate and well-controlled human pregnancy studies are lacking.
Mometasone furoate cream should be used during pregnancy only when the expected benefit justifies the potential risk. Current UK labeling recommends avoiding application over large body areas or for prolonged periods during pregnancy.
Breastfeeding
It is not known whether topical administration results in sufficient systemic absorption to produce detectable quantities of corticosteroid in breast milk.
Current UK prescribing information recommends use only after careful assessment of the benefit-risk relationship. If high-dose or prolonged treatment is required, the UK SmPC advises discontinuation of breastfeeding.
Older adults
U.S. clinical studies included patients aged 65 years and older and did not identify overall differences in safety or effectiveness compared with younger adults, although increased sensitivity in some older individuals cannot be excluded.
19. Storage Conditions
For the Egyptian Momsone product information:
Store at a temperature not exceeding 30°C.
Keep out of reach of children.
The storage conditions printed on the currently marketed Momsone carton and package leaflet should take precedence if the approved local instructions have been revised.
20. Additional Sections
Overdosage
Excessive or prolonged topical corticosteroid use may cause sufficient systemic absorption to suppress HPA-axis function and produce secondary adrenal insufficiency.
If clinically significant suppression occurs, management may include withdrawal of treatment, reduction in application frequency, or substitution with a less potent corticosteroid under medical supervision.
Pack
20-g tube of cream, packed in a carton with product information according to the Egyptian Momsone presentation.
Ability to Drive or Operate Machinery
Current UK mometasone furoate 0.1% cream prescribing information states that the medicine has no influence on the ability to drive or use machines.
Patient Counseling
Use Momsone only for the skin condition for which it was prescribed.
Do not use the cream as a cosmetic skin-lightening product.
Do not routinely apply it to the face, groin, axillae, eyelids, or diaper area unless specifically directed by a healthcare professional.
Do not use more frequently, over larger areas, or for longer periods than recommended.
21. Frequently Asked Questions (FAQ)
Q: How often is Momsone 0.1% Cream normally applied?
A thin film is generally applied once daily, unless the physician gives different instructions.
Q: Is Momsone a strong steroid?
Potency classifications differ internationally. U.S. prescribing information describes mometasone furoate cream as being in the medium range, while current UK labeling classifies it as a potent/Group III corticosteroid.
Q: Can Momsone be used on the face?
It should not be routinely used on the face without medical supervision. Current U.S. labeling advises avoiding facial use, while UK guidance allows medically indicated facial treatment using the smallest effective amount for no more than 5 days.
Q: Can it be used in children?
Use below 2 years is not recommended because safety and efficacy have not been established. Children aged 2 years or older should use it only according to medical and locally approved product instructions.
Q: Is Momsone an antifungal or antibiotic cream?
No. Mometasone is a corticosteroid and does not eradicate bacteria or fungi.
Q: Can the treated skin be covered with a bandage?
Not routinely. Occlusion can increase corticosteroid absorption. Use an occlusive dressing only when specifically directed by a physician.
Q: Can it be used for diaper rash?
No. Current U.S. prescribing information specifically states that mometasone furoate cream should not be used for diaper dermatitis. Diapers and plastic pants can also act as occlusive dressings.
Q: What should be done if the condition is not improving?
If meaningful improvement has not occurred within approximately 2 weeks, the diagnosis and treatment should be reassessed.
Q: Can Momsone be used continuously for a long time?
Long-term continuous treatment should generally be avoided because it increases the risks of skin atrophy, systemic corticosteroid effects, and rebound/withdrawal reactions.
Q: Can Momsone cause changes in skin color?
Yes. Hypopigmentation has been reported with topical corticosteroids and with mometasone-containing preparations.
22. References
- DailyMed — Mometasone Furoate Cream USP, 0.1%, U.S. prescribing information. Current labeling provides information on indications, dosing, pediatric use, HPA-axis effects, adverse reactions, pharmacokinetics, interactions, and potency classification.
- electronic Medicines Compendium (emc) — Mometasone Furoate 0.1% w/w Cream, Glenmark Pharmaceuticals Europe Ltd. Updated on emc 26 June 2026; includes current UK indications, contraindications, pediatric instructions, CYP3A interaction information, pregnancy/breastfeeding guidance, withdrawal reactions, pharmacokinetics, and adverse effects.
- electronic Medicines Compendium (emc) — Elocon 0.1% w/w Cream, Organon Pharma (UK) Limited. Current branded UK reference for mometasone furoate cream, including potency classification, contraindications, precautions, pharmacokinetics, adverse effects, and interactions.
- Momsone 0.1% Cream — SEDICO, Egyptian product information. Product-specific strength, manufacturer, pack presentation, storage conditions, and locally approved instructions should be verified against the latest EDA-approved package information.